Expression of porcine reproductive respiratory syndrome virus polypeptides in the same cell
AssigneeAkzo Nobel N.V.
InventorsPetrus Alphonsus Maria Van Woensel, Karl-Klaus Conzelmann
Life of this patent
Estimating the term…
Abstract
The present invention provides a process for the recombinant DNA production of a mature form of the PRRSV ORF 3 or ORF 4 protein. This is achieved by the co-expression of the PRRSV ORF 2, ORF 3 and ORF 4 proteins by the same cell.
Claims12
A process for the preparation of a glycosylated forms of porcine reproductive respiratory syndrome virus (PRRSV) ORF 3 and ORF 4 proteins, comprising the steps of:
- a. culturing a suitable host cell transformed with subgenomic DNA fragments encoding the PRRSV ORF 2, ORF 3 and ORF 4 proteins, or a suitable host cell infected with one or more vector (virus) viruses each of which comprise one or more subgenomic DNA fragments encoding the PRRSV ORF 2, ORF 3 or ORF 4 proteins, under conditions whereby the ORF 2, ORF 3 and ORF 4 proteins are expressed;
- and
- b. harvesting the expressed proteins.
A host cell transformed with subgenomic DNA fragments encoding PRRSV ORF 2, ORF 3 and ORF 4.
A vector virus comprising two or more heterologous DNA fragments selected from the group consisting of the DNA fragments that encode PRRSV ORF 2, ORF 3 and ORF 4 proteins.
A mixture of two or more vector viruses, each vector virus comprising one or more subgenomic PRRSV ORFs, said mixture being able to co-infect a host cell and to express PRRSV ORF 2, ORF 3 and ORF 4 in the cell.
An isolated DNA molecule comprising a subgenomic nucleic acid sequence encoding PRRSV ORF 2, ORF 3 and ORF 4 proteins, each ORF being separately and operatively linked to a promoter.
An isolated, glycosylated, endo-H resistant form of PRRSV ORF 3 or ORF 4 protein.
An immunogenic composition comprising at least one endo-H resistant PRRSV protein selected from the group consisting of ORF 3 and ORF 4, together with a pharmaceutically acceptable carrier or diluent.
An immunogenic composition comprising at least one vector virus that singly or together will express ORF 2, ORF 3 and ORF 4 proteins in a cell, together with a pharmaceutically acceptable carrier or diluent.
Dependencies are inferred from the claim text.